Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity

키워드

참고문헌 (50)

1. 정규원, "Prediction of Cancer Incidence and Mortality in Korea, 2015", Cancer Research and Treatment, 47(2), pp.142~148 (2015), 대한암학회[DOI]
2. Yeh ET, "Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management", J Am Coll Cardiol, 53, pp.2231~2247 (2009)
3. Albini A, "Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention", J Natl Cancer Inst, 102, pp.14~25 (2010)
4. 김상민, "A Case of Severe Coronary Spasm Associated with 5-Fluorouracil Chemotherapy", The Korean Journal of Internal Medicine, 27(3), pp.342~345 (2012), 대한내과학회[DOI]
5. Vejpongsa P, "Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities", J Am Coll Cardiol, 64, pp.938~945 (2014)
6. Angsutararux P, "Chemotherapy-induced cardiotoxicity: overview of the roles of oxidative stress", Oxid Med Cell Longev, 2015, pp.795602~ (2015)
7. 정우백, "Early Cardiac Function Monitoring for Detection of Subclinical Doxorubicin Cardiotoxicity in Young Adult Patients with Breast Cancer", Journal of Breast Cancer, 16(2), pp.178~183 (2013), 한국유방암학회
8. Sawaya H, "Early detection and prediction of cardiotoxicity in chemotherapy-treated patients", Am J Cardiol, 107, pp.1375~1380 (2011)
9. Cardinale D, "Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy", Circulation, 131, pp.1981~1988 (2015)
10. "Common Terminology Criteria for Adverse Events (CTCAE) version 4.0" (2009)[URL]
11. Yoon GJ, "Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?", J Am Coll Cardiol, 56, pp.1644~1650 (2010)
12. Toro-Salazar OH, "Feasibility of echocardiographic techniques to detect subclinical cancer therapeutics-related cardiac dysfunction among high-dose patients when compared with cardiac magnetic resonance imaging", J Am Soc Echocardiogr, 29, pp.119~131 (2016)
13. Curigliano G, "Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines", Ann Oncol, 23(Suppl 7), pp.vii155~vii166 (2012)
14. Corapcioglu F, "Evaluation of anthracycline-induced early left ventricular dysfunction in children with cancer: a comparative study with echocardiography and multigated radionuclide angiography", Pediatr Hematol Oncol, 23, pp.71~80 (2006)
15. Lim CC, "Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes", J Biol Chem, 279, pp.8290~8299 (2004)
16. 최주연, "15MHz 고주파탐촉자를 이용한 백서의 Adriamycin 유발 심근증 모델의 평가", Journal of Cardiovascular Ultrasound, 8(1), pp.78~86 (2000), 한국심초음파학회
17. 최윤석, "흰쥐에서 급성 Adriamycin 유발 심근증과 세포 자멸과의 관계: 15 MHz 고주파 탐촉자를 이용한 연구", Journal of Cardiovascular Ultrasound, 10(2), pp.35~43 (2002), 한국심초음파학회
18. Uhm JS, "Comparison of adriamycin-induced cardiomyopathy in normotensive rats and spontaneously hypertensive rats", J Korean Soc Hypertens J, 12, pp.23~30 (2006)
19. Rochette L, "Anthracyclines", trastuzumab: new aspects of cardiotoxicity and molecular mechanisms, 2015, pp.36, 326~348
20. Salazar-Mendiguchia J, "Anthracycline-mediated cardiomyopathy: basic molecular knowledge for the cardiologist", Arch Cardiol Mex, 84, pp.218~223 (2014)
21. Minotti G, "Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity", Pharmacol Rev, 56, pp.185~229 (2004)
22. L’Ecuyer T, "DNA damage is an early event in doxorubicin-induced cardiac myocyte death", Am J Physiol Heart Circ Physiol, 291, pp.H1273~H1280 (2006)
23. Octavia Y, "Doxorubicin-induced cardiomyopathy:from molecular mechanisms to therapeutic strategies", J Mol Cell Cardiol, 52, pp.1213~1225 (2012)
24. Fu LX, "A new insight into adriamycin-induced cardiotoxicity", Int J Cardiol, 29, pp.15~20 (1990)
25. Minotti G, "Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy", Cancer Res, 61, pp.8422~8428 (2001)
26. Tokarska-Schlattner M, "New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics", J Mol Cell Cardiol, 41, pp.389~405 (2006)
27. Schubert C, "The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review", Brain Behav Immun, 21, pp.413~427 (2007)
28. Chiosi E, "Change in TNF-alpha receptor expression is a relevant event in doxorubicin-induced H9c2 cardiomyocyte cell death", J Interferon Cytokine Res, 27, pp.589~597 (2007)
29. Youn HJ, "Induction of caspase-independent apoptosis in H9c2 cardiomyocytes by adriamycin treatment", Mol Cell Biochem, 270, pp.13~19 (2005)
30. Zhang S, "Identification of the molecular basis of doxorubicin-induced cardiotoxicity", Nat Med, 18, pp.1639~1642 (2012)
31. Vejpongsa P, "Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity", Clin Pharmacol Ther, 95, pp.45~52 (2014)
32. 정우백, "The Expression of Cardiac Ankyrin Repeat Protein in an Animal Model of Adriamycin-Induced Cardiomyopathy", Korean Circulation Journal, 38(9), pp.455~461 (2008), 대한심장학회
33. Levkau B, "Survivin determines cardiac function by controlling total cardiomyocyte number", Circulation, 117, pp.1583~1593 (2008)
34. Swain SM, "Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials", Cancer, 97, pp.2869~2879 (2003)
35. Menna P, "Cardiotoxicity of antitumor drugs", Chem Res Toxicol, 21, pp.978~989 (2008)
36. Altena R, "Cardiovascular toxicity caused by cancer treatment: strategies for early detection", Lancet Oncol, 10, pp.391~399 (2009)
37. Tan-Chiu E, "Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31", J Clin Oncol, 23, pp.7811~7819 (2005)
38. Perez EA, "Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial", J Clin Oncol, 26, pp.1231~1238 (2008)
39. Armstrong GT, "Modifiable risk factors and major cardiac events among adult survivors of childhood cancer", J Clin Oncol, 31, pp.3673~3680 (2013)
40. Suter TM, "Cancer drugs and the heart: importance and management", Eur Heart J, 34, pp.1102~1111 (2013)
41. Thavendiranathan P, "Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review", J Am Coll Cardiol, 63(25 Pt A), pp.2751~2768 (2014)
42. Tarr A, "Early detection of cardiotoxicity by 2D and 3D deformation imaging in patients receiving chemotherapy", Echo Res Pract, 2, pp.81~88 (2015)
43. Poulin F, "Cardiotoxicity due to chemotherapy:role of cardiac imaging", Curr Cardiol Rep, 17, pp.564~ (2015)
44. Tamene AM, "Cardiovascular MR imaging in cardio-oncology", Magn Reson Imaging Clin N Am, 23, pp.105~116 (2015)
45. Cardinale D, "Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy", Circulation, 109, pp.2749~2754 (2004)
46. Yu AF, "Roadmap for biomarkers of cancer therapy cardiotoxicity", Heart, 102, pp.425~430 (2016)
47. de Azambuja E, "Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil-or epirubicin-based chemotherapy", Eur J Cancer, 51, pp.2517~2524 (2015)
48. 박철수, "생쥐의 Adriamycin 유발 심근증 모델에서 IGF-1의심근 보호 효과", Korean Circulation Journal, 32(12), pp.1116~1123 (2002), 대한심장학회
49. Uhm JS, "Effects of adriamycin and candesartan on the collagen and elastin of the aorta in rats", Clin Hypertens, 20, pp.8~ (2014)
50. Cardinale D, "Strategies to prevent and treat cardiovascular risk in cancer patients", Semin Oncol, 40, pp.186~198 (2013)

관련 논문AI추천